Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | GAPDH | P04406 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16555219 | 1.00 | ADORA3 (0.57) | ADORA3ADORA2AADORA2BLMNANT5E | |
| SCHEMBL2057319 | 0.90 | ADORA2A (0.64) | ADORA3ADORA2AADORA2BLMNANT5E | |
| SCHEMBL1071617 | 0.85 | ADORA3 (0.58) | ADORA3ADORA2AADORA2BLMNANT5E | |
| SCHEMBL27584187 | 0.84 | ADORA3 (0.52) | ADORA3ADORA2AADORA2BLMNANT5E | |
| SCHEMBL4383154 | 0.83 | CYP1A2 (0.41) | ADORA3ADORA2AADORA2BLMNANT5E | |
| SCHEMBL3654018 | 0.83 | PNP (0.56) | LMNAHIF1ASMN1; SMN2 | |
| SCHEMBL16555404 | 0.82 | LMNA (0.62) | ADORA3ADORA2AADORA2BLMNANT5E | |
| SCHEMBL899617 | 0.82 | LMNA (0.62) | ADORA3ADORA2AADORA2BLMNANT5E | |
| SCHEMBL3970946 | 0.82 | LMNA (0.62) | ADORA3ADORA2AADORA2BLMNANT5E | |
| SCHEMBL5033515 | 0.82 | LMNA (0.62) | ADORA3ADORA2AADORA2BLMNANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096203-A1 | TARGETING A CHIMERIC RNA FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2023056044-A1 | POLYNUCLEOTIDES ENCODING RELAXIN FOR THE TREATMENT OF FIBROSIS AND/OR CARDIOVASCULAR DISEASE | MODERNATX, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-3442590-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | Modernatx, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017180917-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-9422294-B2 | Cyclic compound, method for producing cyclic compound, and method for modifying biological molecule | JNC CORPORATION (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20140364594-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | JNC CORP (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8901312-B2 | Cyclic compound, method for producing cyclic compound, and method for modifying biological molecule | JNC CORPORATION (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8648054-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | ROCHE PALO ALTO LLC (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130011901-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | JNC CORPORATION (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20110020799-A1 | Screening method for damaged DNA repairing substance | NAGASAKI UNIVERSITY | 2011-01-27 | — | — | US | disclosed |
| US-20100173793-A1 | PEPTIDE / PROTEIN IDENTIFICATION USING PHOTOREACTIVE CARRIERS FOR THE IMMOBILISATION OF THE LIGANDS | UNIVERSITY OF WARWICK (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-1926992-A2 | PEPTIDE / PROTEIN IDENTIFICATION USING PHOTOREACTIVE CARRIERS FOR THE IMMOBILISATION OF THE LIGANDS | THE UNIVERSITY OF WARWICK (GB) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007020453-A2 | PEPTIDE / PROTEIN IDENTIFICATION USING PHOTOREACTIVE CARRIERS FOR THE IMMOBILISATION OF THE LIGANDS | UNIVERSITY OF WARWICK (GB) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364594-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | PTMS, CD38, TIMCC | ADORA3 1166/4885ADORA2A 1265/4885ADORA2B 1933/4885 |
| US-20100173793-A1 | PEPTIDE / PROTEIN IDENTIFICATION USING PHOTOREACTIVE CARRIERS FOR THE IMMOBILISATION OF THE LIGANDS | CLTA, CD40, DNPEP | ADORA3 2590/4885ADORA2A 3956/4885ADORA2B 3927/4885 |
| US-20130011901-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | PTMS, CD38, TIMCC | ADORA3 1166/4885ADORA2A 1265/4885ADORA2B 1933/4885 |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | ADORA3 583/4885ADORA2A 590/4885ADORA2B 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.